Colchicine and Leukopenia: Clinical Implications

Erdal Sag; Yagmur Bayindir; Aydin Adiguzel; Selcan Demir; Yelda Bilginer; Selin Aytac; Seza Ozen

doi:10.1016/j.jpeds.2020.03.065

Colchicine and Leukopenia: Clinical Implications

J Pediatr. 2020 Sep:224:166-170.e1. doi: 10.1016/j.jpeds.2020.03.065. Epub 2020 May 13.

Authors

Erdal Sag¹, Yagmur Bayindir¹, Aydin Adiguzel¹, Selcan Demir¹, Yelda Bilginer¹, Selin Aytac², Seza Ozen³

Affiliations

¹ Division of Pediatric Rheumatology, Department of Pediatrics, Ankara, Turkey.
² Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University, Ankara, Turkey.
³ Division of Pediatric Rheumatology, Department of Pediatrics, Ankara, Turkey. Electronic address: [email protected].

PMID: 32417084
DOI: 10.1016/j.jpeds.2020.03.065

Abstract

Colchicine is the mainstay of treatment for familial Mediterranean fever. We investigated the frequency of leukopenia in 213 patients with familial Mediterranean fever treated with standard doses of colchicine (0.5-2.0 mg/day). We found that 23 patients (10.8%) had reversible leukopenia, 3 moderate, and none severe and that their rate of infections was not increased.

Keywords: FMF; colchicine; leukopenia.

Publication types

Case Reports

MeSH terms

Case-Control Studies
Child
Child, Preschool
Colchicine / administration & dosage
Colchicine / adverse effects*
Colchicine / pharmacology
Dose-Response Relationship, Drug
Familial Mediterranean Fever / drug therapy*
Female
Humans
Leukopenia / chemically induced*
Leukopenia / diagnosis
Leukopenia / drug therapy
Longitudinal Studies
Male
Tubulin Modulators / administration & dosage
Tubulin Modulators / adverse effects*
Tubulin Modulators / pharmacology

Substances

Tubulin Modulators
Colchicine